Aprea Therapeutics (NASDAQ:APRE – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01, FiscalAI reports. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 96.33%.
Aprea Therapeutics Price Performance
Shares of NASDAQ APRE traded down $0.02 during midday trading on Wednesday, reaching $0.88. 241,006 shares of the stock were exchanged, compared to its average volume of 1,650,138. The business has a 50-day simple moving average of $0.82 and a two-hundred day simple moving average of $0.92. The company has a market capitalization of $10.89 million, a price-to-earnings ratio of -0.44 and a beta of 1.48. Aprea Therapeutics has a 12 month low of $0.55 and a 12 month high of $2.22.
Analysts Set New Price Targets
Several analysts have recently weighed in on APRE shares. Zacks Research raised shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. HC Wainwright dropped their price objective on shares of Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating for the company in a report on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Monday, April 20th. Oppenheimer started coverage on shares of Aprea Therapeutics in a report on Thursday, May 7th. They set an “outperform” rating and a $5.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Aprea Therapeutics in a report on Tuesday, March 31st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Aprea Therapeutics has a consensus rating of “Hold” and an average price target of $4.40.
Hedge Funds Weigh In On Aprea Therapeutics
An institutional investor recently bought a new position in Aprea Therapeutics stock. DRW Securities LLC purchased a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 120,651 shares of the company’s stock, valued at approximately $103,000. DRW Securities LLC owned approximately 1.73% of Aprea Therapeutics as of its most recent SEC filing. 34.19% of the stock is currently owned by hedge funds and other institutional investors.
Aprea Therapeutics Company Profile
Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.
Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.
Featured Articles
- Five stocks we like better than Aprea Therapeutics
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
